Arrowhead Pharmaceuticals Advances Two RNAi-Based Obesity Candidates
ARO-INHBE and ARO-HSD17B13 to Enter Clinical Development
Pasadena, Calif. - Feb. 27, 2023 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a biotechnology company developing medicines that treat intractable diseases through RNA interference (RNAi), today presented preclinical data and detailed its plans for two new RNAi-based obesity candidates, ARO-INHBE and ARO-HSD17B13, at the American Diabetes Association (ADA) 83rd Scientific Sessions.
ARO-INHBE
ARO-INHBE is designed to reduce the production of inhibin beta E (INHBE), a protein that regulates appetite and energy expenditure. Preclinical studies have shown that ARO-INHBE significantly reduces body weight and improves glucose metabolism in obese animal models.
- ARO-INHBE reduced body weight by up to 20% in obese mice.
- ARO-INHBE improved glucose tolerance by up to 50% in obese mice.
- ARO-INHBE was well-tolerated in all animal studies.
Arrowhead plans to initiate a Phase 1/2 clinical trial of ARO-INHBE in the second half of 2023.
ARO-HSD17B13
ARO-HSD17B13 is designed to reduce the production of 17β-hydroxysteroid dehydrogenase 13 (HSD17B13), an enzyme that converts inactive cortisone to active cortisol. Preclinical studies have shown that ARO-HSD17B13 significantly reduces body weight and improves lipid metabolism in obese animal models.
- ARO-HSD17B13 reduced body weight by up to 15% in obese mice.
- ARO-HSD17B13 reduced fasting blood glucose levels by up to 25% in obese mice.
- ARO-HSD17B13 reduced circulating triglycerides by up to 50% in obese mice.
Arrowhead plans to initiate a Phase 1/2 clinical trial of ARO-HSD17B13 in the second half of 2023.
Conclusion
Arrowhead's new RNAi-based obesity candidates, ARO-INHBE and ARO-HSD17B13, have the potential to provide new and effective treatments for obesity and its related complications. Arrowhead is committed to advancing these candidates through clinical development and bringing them to patients as quickly as possible.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops RNAi-based medicines for difficult-to-treat diseases. RNAi (RNA interference) is a natural cellular process that regulates gene expression. By harnessing the RNAi pathway, Arrowhead can selectively silence specific genes that are the cause of disease.
Komentar